Cargando…

Routine Ophthalmological Examination Rates in Adults with Sickle Cell Disease Are Low and Must Be Improved

The American Academy of Ophthalmology and the National Heart, Lung and Blood Institute recommend patients with sickle cell disease (SCD) undergo dilated funduscopic exams (DFE) every 1–2 years to screen for sickle retinopathy. There is a paucity of data on the adherence rate to these guidelines; a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zulueta, Patricia, Minniti, Caterina P., Rai, Anvit, Toribio, Tiana J., Moon, Jee-Young, Mian, Umar K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962573/
https://www.ncbi.nlm.nih.gov/pubmed/36834146
http://dx.doi.org/10.3390/ijerph20043451
Descripción
Sumario:The American Academy of Ophthalmology and the National Heart, Lung and Blood Institute recommend patients with sickle cell disease (SCD) undergo dilated funduscopic exams (DFE) every 1–2 years to screen for sickle retinopathy. There is a paucity of data on the adherence rate to these guidelines; a retrospective study was performed to evaluate our institution’s adherence. A chart review of 842 adults with SCD, seen 3/2017–3/2021 in the Montefiore healthcare system (All Patients), was done. Only about half of All Patients (n = 842) had >1 DFE during the study period (Total Examined Patients, n = 415). The Total Examined Patients were categorized as screening, those without retinopathy (Retinopathy−, n = 199), or follow-up, including individuals previously diagnosed with retinopathy (Retinopathy+, n = 216). Only 40.3% of screening patients (n = 87) had DFE at least biennially. As expected, there was a significant decrease in the average DFE rate of the Total Examined Patients after the COVID-19 pandemic started (13.6%) compared to pre-COVID (29.8%, p < 0.001). Similarly, there was a significant decrease in the screening rate of Retinopathy− patients from 18.6% on average pre-COVID to 6.7% during COVID (p < 0.001). This data shows the sickle retinopathy screening rate is low and innovative approaches may need to be employed to remedy this issue.